通用名称为安理申

盐酸多奈哌齐5毫克，10毫克，23mg;标签。

法律分类：
RX

安理申的药理类

可逆的乙酰胆碱酯酶抑制剂（哌DERIV）。

安理申制造商
卫材制药

主治为安理申
阿尔茨海默氏痴呆症。

成人剂量为安理申
标签：燕子与水的整体。的ODT：舌头上溶解，然后喝水。轻中度：最初5毫克每天在睡前，可能会增加至10mg，每日4-6周后，常用剂量：5mg或10mg每日一次。中度重度：最初10毫克每天在睡前，可能会增加至23mg每日3个月后，常用剂量：10mg或23mg每日一次。

儿童剂量为安理申
不适用。

另外：
名为Aricept ODT

警告/安理申的注意事项
心脏传导条件。消化性溃疡。消化道出血的监测。癫痫发作。哮喘或慢性阻塞性肺病。胃肠道或顾梗阻。体重<55公斤。怀孕（Cat.C）。哺乳的母亲。

为多奈哌齐的相互作用
影响CYP2D6和CYP3A4的药物，可能会影响的淘汰率。拮抗抗胆碱能药物。会增强琥珀型肌肉松弛剂，其他胆碱酯酶抑制剂，胆碱能激动剂（如bethanecol）。伴随NSAIDs可能增加胃肠道出血的风险。

安理申的不良反应
胃肠不适，失眠，肌肉痉挛，疲劳，食欲不振，体重减轻（尤其是使用23mg/day剂量）。

安理申是如何提供的？
标签5毫克，10毫克，30，90，1000;23mg-30，90;的ODT-30

ARICEPT Indication and Important Safety Information

Indication
ARICEPT is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease (AD).
IMPORTANT SAFETY INFORMATION
ARICEPT (donepezil HCl) is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.
ARICEPT, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. ARICEPT should be used cautiously in patients undergoing anesthesia.
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. They may also have vagotonic effects on the sinoatrial and atrioventricular nodes. This may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of ARICEPT.
ARICEPT, as a predictable consequence of its pharmacological properties, has been shown to produce diarrhea, nausea, and vomiting. Although in most cases nausea and vomiting have been mild and transient, sometimes lasting one to three weeks, and have resolved during continued use of ARICEPT, patients should be observed closely at the initiation of treatment and after dose increase.
As a cholinesterase inhibitor, ARICEPT has the potential to interfere with the activity of anticholinergic medications, and increase gastric acid secretion. Results of a controlled clinical study with ARICEPT 23 mg/day showed an increase, relative to 10 mg/day, in the incidence of peptic ulcer disease (0.4% vs 0.2%) and gastrointestinal bleeding from any site (1.1% vs 0.6%). Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.
The use of ARICEPT 23 mg/day is associated with weight loss, thus consideration should be given when prescribing to patients of lower weight. In a clinical trial, weight loss was reported in 4.7% of patients on ARICEPT 23 mg/day vs 2.5% on 10 mg/day. Compared to their baseline weights, 8.4% of patients taking ARICEPT 23 mg/day were found to have a weight decrease of ≥7%, while 4.9% on 10 mg/day were found to have weight loss of ≥7% at the end of the study. In this clinical trial, among patients in the ARICEPT 23 mg/day treatment group, those weighing <55 kg (121 lb) reported more nausea, vomiting, and decreased weight than those weighing 55 kg (121 lb) or more, and more withdrawals due to these adverse events were seen.
Cholinomimetics may cause bladder outflow obstruction, although this was not observed in clinical trials of ARICEPT. Cholinomimetics are believed to have some potential to cause generalized convulsions. However, seizure activity also may be a manifestation of Alzheimer's disease.
Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. In addition, a synergistic effect may be expected with concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists.
In clinical trials, the most common adverse events seen with ARICEPT 5 mg/day and 10 mg/day compared to placebo were nausea (11% vs 6%), diarrhea (10% vs 5%), insomnia (9% vs 6%), vomiting (5% vs 3%), muscle cramps (6% vs 2%), fatigue (5% vs 3%), and anorexia (4% vs 2%).
In a clinical trial, the most common adverse events in patients receiving ARICEPT 23 mg/day compared to 10 mg/day were nausea (12% vs 3%), vomiting (9% vs 3%), diarrhea (8% vs 5%), weight loss (5% vs 3%), anorexia (5% vs 2%), and dizziness (5% vs 3%). The incidence of nausea and vomiting was markedly greater in patients taking ARICEPT 23 mg/day vs patients continued on 10 mg/day. The rate of discontinuation due to adverse events from this clinical trial was higher for ARICEPT 23 mg/day (18.6%) than for 10 mg/day (7.9%).
Dosing information
The indicated doses are: 5 mg/day for mild to moderate AD; 10 mg/day for mild, moderate, and severe AD; and
23 mg/day for moderate to severe AD.
The recommended starting dose of ARICEPT is 5 mg/day. A dose of 10 mg/day can be administered once patients have been on 5 mg/day for 4 to 6 weeks; 23 mg/day can be administered once patients have been on 10 mg/day for at least 3 months.

Related Disease:

Alzheimer's dementia

Generic Name for ARICEPT

Donepezil HCl 5mg, 10mg, 23mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ARICEPT

Reversible acetylcholinesterase inhibitor (piperidine deriv).

Manufacturer of ARICEPT

Eisai Pharmaceuticals

Indications for ARICEPT

Alzheimer's dementia.

Adult dose for ARICEPT

Tabs: Swallow whole with water. ODT: dissolve on tongue, then drink water. Mild-moderate: Initially 5mg daily at bedtime, may increase to 10mg daily after 4–6 weeks; usual dose: 5mg or 10mg once daily. Moderate-severe: initially 10mg daily at bedtime, may increase to 23mg daily after 3 months; usual dose: 10mg or 23mg once daily.

Children's dosing for ARICEPT

Not applicable.

Also:

Warnings/Precautions for ARICEPT

Cardiac conduction conditions. Peptic ulcer. Monitor for GI bleeding. Seizures. Asthma or COPD. GI or GU obstruction. Body weight <55kg. Pregnancy (Cat.C). Nursing mothers.

Interactions for ARICEPT

Drugs that affect CYP2D6 and CYP3A4 may affect rate of elimination. Antagonizes anticholinergics. May potentiate succinylcholine-type muscle relaxants, other cholinesterase inhibitors, cholinergic agonists (eg, bethanecol). Concomitant NSAIDs may increase risk of GI bleed.

Adverse Reactions for ARICEPT

GI upset, insomnia, muscle cramps, fatigue, anorexia, weight loss (esp. using 23mg/day dose).

How is ARICEPT supplied?

Tabs 5mg, 10mg—30, 90, 1000; 23mg—30, 90; ODT—30